1. Muscle MRI as a useful biomarker in hereditary transthyretin amyloidosis: A pilot study
- Author
-
Primiano, G., Verdolotti, T., D'Apolito, G., Di Paolantonio, A., Guglielmino, V., Romano, A., Lucioli, G., Luigetti, M., Servidei, S., Primiano G., Verdolotti T., D'Apolito G., Di Paolantonio A., Guglielmino V., Romano A., Lucioli G., Luigetti M. (ORCID:0000-0001-7539-505X), Servidei S. (ORCID:0000-0001-8478-2799), Primiano, G., Verdolotti, T., D'Apolito, G., Di Paolantonio, A., Guglielmino, V., Romano, A., Lucioli, G., Luigetti, M., Servidei, S., Primiano G., Verdolotti T., D'Apolito G., Di Paolantonio A., Guglielmino V., Romano A., Lucioli G., Luigetti M. (ORCID:0000-0001-7539-505X), and Servidei S. (ORCID:0000-0001-8478-2799)
- Abstract
Hereditary transthyretin amyloidosis (ATTRv, v for variant) is a severe and heterogeneous multisystem condition with a prevalent peripheral nervous system impairment, due to mutations in the transthyretin gene. Considering the introduction of different disease-modifying therapies in the last few years, a need of reliable biomarkers is emerging. In this study, we evaluated muscle MRI in a cohort of ATTRv patients in order to establish if the severity of muscle involvement correlated with disease severity. Linear regression analysis showed a significant positive correlation between the total fatty infiltration score and NIS, NIS-LL, and Norfolk, and an inverse correlation with Sudoscan registered from feet. In conclusion, we demonstrated the role of muscle MRI in ATTRv as possible disease biomarker, both for diagnostic purposes and for assessing the severity of the disease.
- Published
- 2021